Aridis Pharmaceuticals, Inc.
5941 Optical Court
San Jose
California
95138
United States
Tel: 408-385-1742
Fax: 408-960-3822
Website: http://www.aridispharma.com/
118 articles about Aridis Pharmaceuticals, Inc.
-
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
12/15/2023
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
-
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
11/3/2023
Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.
-
Aridis Pharmaceuticals Announces $2 Million Offering
8/2/2023
Aridis Pharmaceuticals, Inc. today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share.
-
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
7/17/2023
Aridis Pharmaceuticals, Inc. announced positive feedback from the European Medicines Agency on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients.
-
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
7/12/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.
-
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
6/20/2023
Aridis Pharmaceuticals, Inc. today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
-
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
6/8/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today reported financial and corporate results for its first quarter ended March 31, 2023.
-
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
5/31/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301.
-
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
5/25/2023
Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 23, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.
-
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
4/26/2023
Aridis Pharmaceuticals, Inc. announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.
-
Aridis Provides Corporate Update
3/31/2023
Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.
-
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
3/14/2023
Aridis Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering.
-
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
1/25/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).
-
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
1/17/2023
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients.
-
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
12/28/2022
Aridis Pharmaceuticals, Inc. will host a conference call and audio-only webcast on Wednesday, January 25, at 4:15 p.m. ET to provide a business and pipeline update, including a discussion of topline data from the Company’s Phase 3 study of AR-301 in adjunctive treatment of S. aureus ventilator associated pneumonia.
-
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12/12/2022
Aridis Pharmaceuticals, Inc. today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients.
-
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12/12/2022
Aridis Pharmaceuticals, Inc., a biopharmaceutical company announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis patients.
-
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
12/5/2022
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc.
-
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
11/30/2022
Aridis Pharmaceuticals, Inc. today announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients.
-
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
11/22/2022
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tuesday, November 29, at 11 a.m. EST.